- Home
- GLTO vs KLTO Comparison
GLTO vs KLTO Comparison
Compare GLTO & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- KLTO
- Stock Information
- Founded
- GLTO 2011
- KLTO 2019
- Country
- GLTO Denmark
- KLTO United States
- Employees
- GLTO N/A
- KLTO N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- GLTO Health Care
- KLTO
- Exchange
- GLTO Nasdaq
- KLTO NYSE
- Market Cap
- GLTO 4.5M
- KLTO 5.9M
- IPO Year
- GLTO 2020
- KLTO N/A
- Fundamental
- Price
- GLTO $3.54
- KLTO $1.34
- Analyst Decision
- GLTO Buy
- KLTO
- Analyst Count
- GLTO 1
- KLTO 0
- Target Price
- GLTO $10.00
- KLTO N/A
- AVG Volume (30 Days)
- GLTO 13.7K
- KLTO 22.5M
- Earning Date
- GLTO 08-11-2025
- KLTO 08-15-2025
- Dividend Yield
- GLTO N/A
- KLTO N/A
- EPS Growth
- GLTO N/A
- KLTO N/A
- EPS
- GLTO N/A
- KLTO N/A
- Revenue
- GLTO N/A
- KLTO N/A
- Revenue This Year
- GLTO N/A
- KLTO N/A
- Revenue Next Year
- GLTO N/A
- KLTO N/A
- P/E Ratio
- GLTO N/A
- KLTO N/A
- Revenue Growth
- GLTO N/A
- KLTO N/A
- 52 Week Low
- GLTO $2.01
- KLTO $0.11
- 52 Week High
- GLTO $16.07
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- GLTO 59.96
- KLTO N/A
- Support Level
- GLTO $3.24
- KLTO N/A
- Resistance Level
- GLTO $3.60
- KLTO N/A
- Average True Range (ATR)
- GLTO 0.26
- KLTO 0.00
- MACD
- GLTO -0.01
- KLTO 0.00
- Stochastic Oscillator
- GLTO 60.98
- KLTO 0.00
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.